Oncology

Bio-Thera Solutions Targets Russia for Golimumab Biosimilar

July 23rd 2020

By Skylar Jeremias

China-based Bio-Thera Solutions is breaking into the growing Russian biosimilar market by licensing the marketing rights for its unapproved golimumab biosimilar to Russian biopharmaceutical company Pharmapark.

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 22nd 2020

By Tony Hagen

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Webinar: Choice Is Vital to Biosimilar Savings Picture

July 21st 2020

By Tony Hagen

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.

Oncology Providers Discuss the Emergence of Biosimilars

July 21st 2020

By Tony Hagen

A recent article lays out some of the hurdles the biosimilars industry faces, from the perspectives of oncology providers.

World's First Halal Biosimilar to Be Produced in Malaysia

July 20th 2020

By Tony Hagen

As part of a project to build the first biosimilar factory in Malaysia, one of the initial products would be halal certified.

Celltrion Antiviral Treatment for COVID-19 Makes Progress

July 17th 2020

By Tony Hagen

Celltrion Healthcare said an antiviral drug candidate is moving along in trials as a potential treatment for coronavirus 2019 (COVID-19).

Why Biosimilar Approval Applications Break Down

July 17th 2020

By Tony Hagen

Investigators found that process complexities have created numerous difficulties for biosimilar developers in regulatory filings, but they anticipate that the success rate will improve with experience and improved guidance.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16th 2020

By Tony Hagen

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.

New Biologics Are Skewing Exclusivity Periods Longer, Study Says

July 14th 2020

By Tony Hagen

The rise of biologics as a class of prescription spending is fueling a trend toward longer exclusivity periods, which ultimately makes access more remote, authors of a new study said.

Celltrion: Infliximab Biosimilar Shows Promise for COVID-19

July 14th 2020

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses how Celltrion's infliximab biosimilar can aid in the treatment of coronavirus disease 2019 (COVID-19)–related inflammation, as well as the company’s launch plans for biosimilars through 2030.